BENSALEM, Pa.--(BUSINESS WIRE)--Jul 9, 2018--Law Offices of Howard G. Smith announces an investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD ) investors concerning the Company and its officers’ possible violations of federal securities laws.

On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors.

Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

If you purchased ACADIA securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to, or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

CONTACT: Law Offices of Howard G. Smith

Howard G. Smith, Esquire





SOURCE: Law Offices of Howard G. Smith

Copyright Business Wire 2018.

PUB: 07/09/2018 09:09 PM/DISC: 07/09/2018 09:09 PM